Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome | Zendy

Cheri Deal | Zendy; Michèle Tony | Zendy; Charlotte Höybye | Zendy; David B. Allen | Zendy; M. Tauber | Zendy; Jens Sandahl Christiansen | Zendy

Open Access

Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome

Author(s) -

Cheri Deal,

Michèle Tony,

Charlotte Höybye,

David B. Allen,

M. Tauber,

Jens Sandahl Christiansen

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-3888

Subject(s) - medicine , guideline , randomized controlled trial , observational study , clinical trial , adverse effect , population , systematic review , informed consent , intensive care medicine , pediatrics , medline , alternative medicine , pathology , environmental health , political science , law

Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research